Markets:

Overview

News

Currencies

International

Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.590 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative' ↗

April 07, 2023

Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.

Via Benzinga

Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage

April 04, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference

March 01, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

What 6 Analyst Ratings Have To Say About Rocket Pharmaceuticals ↗

February 28, 2023

Via Benzinga

The Latest Analyst Ratings for Rocket Pharmaceuticals ↗

January 23, 2023

Via Benzinga

Where Rocket Pharmaceuticals Stands With Analysts ↗

December 06, 2022

Via Benzinga

Expert Ratings for Rocket Pharmaceuticals ↗

December 06, 2022

Via Benzinga

Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention ↗

February 28, 2023

Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia,...

Via Benzinga

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

February 27, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

February 09, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

February 07, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

SVB Leerink Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know ↗

December 06, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

January 13, 2023

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

Via MarketBeat

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

January 09, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗

December 23, 2022

Gainers

Via Benzinga

Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗

December 23, 2022

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...

Via Benzinga

Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗

December 22, 2022

Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher ↗

December 22, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 600 points on Thursday.

Via Benzinga

Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3 ↗

December 22, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday.

Via Benzinga

Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting

December 22, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting

December 12, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Completes Acquisition of Renovacor

December 01, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 28, 2022

Via Benzinga

Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket ↗

November 28, 2022

Gainers Talkspace, Inc. (NASDAQ: TALK) shares rose 48.3% to $0.89 in pre-market trading. Talkspace recently named Jon Cohen as CEO.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 28, 2022

Welcome back, trader! It's time to check out the biggest pre-market stock movers that traders will want to know about on Monday!

Via InvestorPlace

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

This Stock Is Up 106% In 2022 And Analysts Love It, But Jim Cramer Says 'There's Too Much Political Risk' ↗

November 15, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies."

Via Benzinga

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗

November 18, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.